OpenLB
Open Library of Bioscience
Advanced Search
Current opinion in nephrology and hypertension
03 01, 2021;30 (2): 231-236.

Cardiovascular disease in children with chronic kidney disease.

Anne M Kouri, Michelle N Rheault
Author Information
  1. Anne M Kouri: University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA.
PMID: 33464005 DOI: 10.1097/MNH.0000000000000684

Abstract

PURPOSE OF REVIEW: Cardiovascular disease (CVD) is a significant cause of morbidity and mortality in children with chronic kidney disease (CKD). The cause of CVD in children with CKD is multifactorial and there are new and emerging data regarding prevalence and risk factors for CVD in this population.
RECENT FINDINGS: A number of recent publications from longitudinal cohort studies of children with CKD have greatly increased our knowledge about the prevalence and risk factors for CVD including hypertension, obesity and Dyslipidaemia. Masked hypertension and isolated nocturnal hypertension both correlate with surrogate markers of CVD in children. obesity and adiposity are associated with an increased risk of CVD. Markers other than BMI such as waist to height ratio and fat-free tissue to fat tissue ratio better correlate with the presence of CVD in children. Dyslipidaemia is extremely prevalent in the paediatric CKD population, but there is a lack of consensus on treatment. More data on the relationship between bone mineral disease and CVD continue to emerge including an association between hyperparathyroidism and isolated nocturnal hypertension.
SUMMARY: Children with CKD have multiple potentially modifiable risk factors for CVD. Research focused on CVD outcomes in children is needed.

References

  1. Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. Pediatr Nephrol 2007; 22:1999–2009.
  2. Chavers BM, Molony JT, Solid CA, et al. One-year mortality rates in US children with end-stage renal disease. Am J Nephrol 2015; 41:121–128.
  3. Chavers BM, Herzog CA. The spectrum of cardiovascular disease in children with predialysis chronic kidney disease. Adv Chronic Kidney Dis 2004; 11:319–327.
  4. Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 2012; 23:578–585.
  5. Mitsnefes MM, Laskin BL, Dahhou M, et al. Mortality risk among children initially treated with dialysis for end-stage kidney disease. JAMA 2013; 309:1921–1929.
  6. Querfeld U, Schaefer F. Cardiovascular risk factors in children on dialysis: an update. Pediatr Nephrol 2020; 35:41–57.
  7. Modi ZJ, Lu Y, Ji N, et al. Risk of cardiovascular disease and mortality in young adults with end-stage renal disease: an analysis of the US Renal Data System. JAMA Cardiol 2019; 4:353–362.
  8. Ku E, McCulloch CE, Ahearn P, et al. Trends in cardiovascular mortality among a cohort of children and young adults starting dialysis in 1995 to 2015. JAMA Netw Open 2020; 3:e2016197.
  9. Azukaitis K, Jankauskiene A, Schaefer F, Shroff R. Pathophysiology and consequences of arterial stiffness in children with chronic kidney disease. Pediatr Nephrol 2020; https://doi.org/10.1007/s00467-020-04732-y [DOI: 10.1007/s00467-020-04732-y]
  10. Lopes R, Morais MB, Oliveira FLC, et al. Evaluation of carotid intima-media thickness and factors associated with cardiovascular disease in children and adolescents with chronic kidney disease. J Pediatr 2019; 95:696–704.
  11. Andersson C, Johnson AD, Benjamin EJ, et al. 70-year legacy of the Framingham Heart Study. Nat Rev Cardiol 2019; 16:687–698.
  12. Baldassarre D, Amato M, Pustina L, et al. Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. Atherosclerosis 2007; 191:403–408.
  13. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115:459–467.
  14. Okwuosa TM, Soliman EZ, Lopez F, et al. Left ventricular hypertrophy and cardiovascular disease risk prediction and reclassification in blacks and whites: the Atherosclerosis Risk in Communities Study. Am Heart J 2015; 169:155–161. e155.
  15. Schaefer F, Doyon A, Azukaitis K, et al. Cardiovascular phenotypes in children with CKD: the 4C study. Clin J Am Soc Nephrol 2017; 12:19–28.
  16. Furth SL, Cole SR, Moxey-Mims M, et al. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 2006; 1:1006–1015.
  17. Brady TM, Roem J, Cox C, et al. Adiposity, sex, and cardiovascular disease risk in children with CKD: a longitudinal study of youth enrolled in the Chronic Kidney Disease in Children (CKiD) Study. Am J Kidney Dis 2020; 76:166–173.
  18. Brady TM, Schneider MF, Flynn JT, et al. Carotid intima-media thickness in children with CKD: results from the CKiD study. Clin J Am Soc Nephrol 2012; 7:1930–1937.
  19. Schmidt BMW, Sugianto RI, Thurn D, et al. Early effects of renal replacement therapy on cardiovascular comorbidity in children with end-stage kidney disease: findings from the 4C-T study. Transplantation 2018; 102:484–492.
  20. Masuda T, Hamasaki Y, Kubota M, et al. Changes in cardiac function after renal transplantation in children: significance of pretransplantation left ventricular hypertrophy. Pediatr Transplant 2019; 23:e13558.
  21. Khouzam N, Wesseling-Perry K. Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease. Pediatr Nephrol 2019; 34:1–10.
  22. Wuhl E, Trivelli A, Picca S, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361:1639–1650.
  23. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140:
  24. Lee J, McCulloch CE, Flynn JT, et al. Prognostic value of ambulatory blood pressure load in pediatric CKD. Clin J Am Soc Nephrol 2020; 15:493–500.
  25. Urbina EM, Mendizabal B, Becker RC, et al. Association of blood pressure level with left ventricular mass in adolescents. Hypertension 2019; 74:590–596.
  26. Chua A, Cramer C, Moudgil A, et al. Kidney transplant practice patterns and outcome benchmarks over 30 years: the 2018 report of the NAPRTCS. Pediatr Transplant 2019; 23:e13597.
  27. Suszynski TM, Rizzari MD, Gillingham KJ, et al. Antihypertensive pharmacotherapy and long-term outcomes in pediatric kidney transplantation. Clin Transplant 2013; 27:472–480.
  28. Babu M, Drawz P. Masked hypertension in CKD: increased prevalence and risk for cardiovascular and renal events. Curr Cardiol Rep 2019; 21:58.
  29. Düzova A, Karabay Bayazit A, Canpolat N, et al. Isolated nocturnal and isolated daytime hypertension associate with altered cardiovascular morphology and function in children with chronic kidney disease: findings from the Cardiovascular Comorbidity in Children with Chronic Kidney Disease study. J Hypertens 2019; 37:2247–2255.
  30. Nehus E, Mitsnefes M. Childhood obesity and the metabolic syndrome. Pediatr Clin North Am 2019; 66:31–43.
  31. Furth SL, Abraham AG, Jerry-Fluker J, et al. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:2132–2140.
  32. Karava V, Printza N, Dotis J, et al. Body composition and arterial stiffness in pediatric patients with chronic kidney disease. Pediatr Nephrol 2019; 34:1253–1260.
  33. Sgambat K, Roem J, Mitsnefes M, et al. Waist-to-height ratio, body mass index, and cardiovascular risk profile in children with chronic kidney disease. Pediatr Nephrol 2018; 33:1577–1583.
  34. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999; 281:727–735.
  35. Saland JM, Kupferman JC, Pierce CB, et al. Change in dyslipidemia with declining glomerular filtration rate and increasing proteinuria in children with CKD. Clin J Am Soc Nephrol 2019; 14:1711–1718.
  36. Baek HS, Kim SH, Kang HG, et al. Dyslipidemia in pediatric CKD patients: results from KNOW-PedCKD (KoreaN cohort study for Outcomes in patients With Pediatric CKD). Pediatr Nephrol 2020; 35:1455–1461.
  37. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338:1650–1656.
  38. Magnussen CG, Raitakari OT, Thomson R, et al. Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study. Circulation 2008; 117:32–42.
  39. Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 2007; 22:1095–1112.
  40. Ashoor IF, Mansfield SA, O'Shaughnessy MM, et al. Prevalence of cardiovascular disease risk factors in childhood glomerular diseases. J Am Heart Assoc 2019; 8:e012143.
  41. Devine PA, Courtney AE, Maxwell AP. Cardiovascular risk in renal transplant recipients. J Nephrol 2019; 32:389–399.
  42. Hooper DK, Williams JC, Carle AC, et al. The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 2013; 28:939–949.
  43. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292:331–337.
  44. Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46:1160–1166.
  45. McAlister L, Pugh P, Greenbaum L, et al. The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis-clinical practice recommendation from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 2020; 35:501–518.
  46. Paschou SA, Kosmopoulos M, Nikas IP, et al. The impact of obesity on the association between vitamin D deficiency and cardiovascular disease. Nutrients 2019; 11:
  47. Takashi Y, Wakino S, Minakuchi H, et al. Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. J Bone Miner Metab 2020; 38:70–77.
  48. Mehta R, Cai X, Lee J, et al. Serial fibroblast growth factor 23 measurements and risk of requirement for kidney replacement therapy: the CRIC (Chronic Renal Insufficiency Cohort) study. Am J Kidney Dis 2020; 75:908–918.
  49. Mitsnefes MM, Betoko A, Schneider MF, et al. FGF23 and left ventricular hypertrophy in children with CKD. Clin J Am Soc Nephrol 2018; 13:45–52.
  50. Bergmark BA, Udell JA, Morrow DA, et al. Klotho, fibroblast growth factor-23, and the renin-angiotensin system: an analysis from the PEACE trial. Eur J Heart Fail 2019; 21:462–470.
  51. Lerch C, Shroff R, Wan M, et al. Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease. Nephrol Dial Transplant 2018; 33:2208–2217.
  52. Liu C, Gidlund EK, Witasp A, et al. Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease. Am J Physiol Renal Physiol 2019; 317:F1122–F1131.
  53. Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4:1551–1558.
  54. Holle J, Querfeld U, Kirchner M, et al. Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease. Pediatr Nephrol 2019; 34:2571–2582. This publication from the 4C study showed that higher levels of gut-derived uremic toxins are associated with cIMT and PWV in children with CKD.
  55. Weaver DJ, Mitsnefes M. Cardiovascular disease in children and adolescents with chronic kidney disease. Semin Nephrol 2018; 38:559–569.
  56. Rheault MN, Molony JT, Nevins T, et al. Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis. Kidney Int 2017; 91:177–182.
  57. Woroniecki RP, Ng DK, Limou S, et al. Renal and cardiovascular morbidities associated with APOL1 status among African-American and non-African-American children with focal segmental glomerulosclerosis. Front Pediatr 2016; 4:122.
  58. Santos LB, Borges LM, Souza LV, et al. Is low birth weight an additional risk factor for hypertension in paediatric patients after kidney transplantation? J Dev Orig Health Dis 2020; 11:3–6. This study showed for the first time that history of low birth weight is associated with risk of hypertension after kidney transplantation in children. This highlights the importance of asking birth history for all of our patients to better understand both kidney and cardiovascular risk.
  59. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3:259–305.
  60. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4: (Suppl 7): 13–53.
  61. Seifert ME, Dahale DS, Kamel M, et al. The Improving Renal Outcomes Collaborative: blood pressure measurement in transplant recipients. Pediatrics 2020; 146.
  62. Major RW, Cheung CK, Gray LJ, Brunskill NJ. Statins and cardiovascular primary prevention in CKD: a meta-analysis. Clin J Am Soc Nephrol 2015; 10:732–739.
  63. Tonelli M, Muntner P, Lloyd A, et al. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol 2013; 24:979–986.
  64. Expert Panel on Integrated Guidelines for Cardiovascular H, Risk Reduction in C, AdolescentsExpert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128: (Suppl 5): S213–S256.
  65. Avis HJ, Hutten BA, Gagne C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010; 55:1121–1126.
  66. Shroff R, Wan M, Nagler EV, et al. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis. Nephrol Dial Transplant 2017; 32:1098–1113.

MeSH Term

Cardiovascular Diseases
Child
Humans
Hypertension
Longitudinal Studies
Renal Insufficiency, Chronic
Risk Factors
Journal Article Review
Article has an altmetric score of 4

Word Cloud

Created with Highcharts 10.0.0CVDchildrendiseaseCKDriskhypertensionfactorsCardiovascularcausechronickidneydataprevalencepopulationincreasedincludingisolatednocturnalcorrelateratiotissuePURPOSEOFREVIEW:significantmorbiditymortalitymultifactorialnewemergingregardingRECENTFINDINGS:numberrecentpublicationslongitudinalcohortstudiesgreatlyknowledgeobesitydyslipidaemiaMaskedsurrogatemarkersObesityadiposityassociatedMarkersBMIwaistheightfat-freefatbetterpresenceDyslipidaemiaextremelyprevalentpaediatriclackconsensustreatmentrelationshipbonemineralcontinueemergeassociationhyperparathyroidismSUMMARY:ChildrenmultiplepotentiallymodifiableResearchfocusedoutcomesneeded

Similar Articles

Cited By